H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB) Oct 2, 2026 06:59AM
H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB) Sep 16, 2026 06:58AM
Piper Sandler Starts Agomab Therapeutics (AGMB) at Overweight Aug 25, 2026 04:06AM
Cantor Fitzgerald Starts Agomab Therapeutics (AGMB) at Overweight Aug 19, 2026 06:13AM
B.Riley Starts Agomab Therapeutics (AGMB) at Buy Jul 23, 2026 08:28AM


Jun 22, 2026 06:11AM H.C. Wainwright Starts Agomab Therapeutics (AGMB) at Buy
Mar 26, 2026 07:01AM Agomab receives US patent for lung fibrosis drug candidate AGMB-447
Mar 3, 2026 06:32AM Leerink Partners Starts Agomab Therapeutics (AGMB) at Outperform
Mar 3, 2026 04:26AM Morgan Stanley Starts Agomab Therapeutics (AGMB) at Overweight
Mar 3, 2026 02:08AM JPMorgan Starts Agomab Therapeutics (AGMB) at Overweight
Jan 29, 2026 07:34AM Agomab (AGMB) files for 12.5M share Nasdaq IPO at $15-$17/sh
Jan 16, 2026 04:26PM Agomab (AGMB) files for proposed IPO